|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1996-9-6
|
|
pubmed:abstractText |
Although high-dose interleukin-2 (IL-2) can produce durable remissions in a subset of responding patients with renal cell carcinoma (RCC), this occurs in the setting of significant toxicity. The purpose of this study is to define the maximum-tolerated dosage (MTD) of IL-2 and interferon alfa-2a (IFN alpha-2a) that can be administered chronically on an outpatient basis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:ConlonK CKC,
pubmed-author:CreekmoreS PSP,
pubmed-author:FentonR GRG,
pubmed-author:GauseB LBL,
pubmed-author:HolmlundJJ,
pubmed-author:JanikJ EJE,
pubmed-author:KoppW CWC,
pubmed-author:LongoD LDL,
pubmed-author:SharfmanWW,
pubmed-author:SmithJ WJW2nd,
pubmed-author:SteinR LRL,
pubmed-author:SznolMM,
pubmed-author:UrbaW JWJ,
pubmed-author:VanderMolenL ALA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2234-41
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8708712-Adult,
pubmed-meshheading:8708712-Aged,
pubmed-meshheading:8708712-Antineoplastic Agents,
pubmed-meshheading:8708712-Biopterin,
pubmed-meshheading:8708712-Carcinoma, Renal Cell,
pubmed-meshheading:8708712-Cohort Studies,
pubmed-meshheading:8708712-Female,
pubmed-meshheading:8708712-Humans,
pubmed-meshheading:8708712-Injections, Subcutaneous,
pubmed-meshheading:8708712-Interferon-alpha,
pubmed-meshheading:8708712-Interleukin-2,
pubmed-meshheading:8708712-Kidney Neoplasms,
pubmed-meshheading:8708712-Killer Cells, Natural,
pubmed-meshheading:8708712-Male,
pubmed-meshheading:8708712-Middle Aged,
pubmed-meshheading:8708712-Neoplasms,
pubmed-meshheading:8708712-Neopterin,
pubmed-meshheading:8708712-Receptors, Interleukin-2,
pubmed-meshheading:8708712-Recombinant Proteins,
pubmed-meshheading:8708712-Remission Induction
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
|
|
pubmed:affiliation |
Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, USA. bgause@mail.ncifcrf.gov
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
